Budesonide/Formoterol Fumarate
Brand name: Symbicort
Rank #22 of 500 drugs by total cost
$759.4M
Total Cost
1,452,561
Total Claims
$759.4M
Total Cost
45,441
Prescribers
$523
Cost per Claim
223,970
Beneficiaries
1,984,484
30-Day Fills
$17K
Avg Cost/Provider
32
Avg Claims/Provider
About Budesonide/Formoterol Fumarate
Budesonide/Formoterol Fumarate (sold as Symbicort) was prescribed 1,452,561 times by 45,441 Medicare Part D providers in 2023, costing the program $759.4M. At $523 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology